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Decreased 123I-meta-iodobenzylguanidine (MIBG) uptake in MIBG myocardial scintigraphy, olfactory dysfunction, and rapid eye
movement (REM) sleep behavior disorder (RBD) are considered useful early indicators of Parkinson disease. We investigated
whether patients with PARK2 mutations exhibited myocardial sympathetic abnormalities using MIBG scintigraphy, olfactory
dysfunction using the Sniﬃn’ Sticks olfactory test, and RBD using polysomnography. None of the examined patients had RBD,
and all except 1 patient exhibited an increase in the olfactory threshold. Moreover, one of the oldest patients exhibited impairment
in identiﬁcation and discrimination. Of 12 patients with PARK2 mutations, 4 patients, who were older than patients without
abnormal uptake, exhibited decreased MIBG uptake. The results obtained in this study suggest that some patients with PARK2
mutations have increased thresholds of olfactory function and myocardial sympathetic dysfunction as nonmotor symptoms.
1.Introduction
Mutations in the parkin gene (PARK2) are considered to
be the predominant cause of early-onset Parkinson disease
particularly when the family history is compatible with
autosomal recessive inheritance [1]. This condition is char-
acterized by early onset of disease, usually before the age of
40 years, dystonia, sleep beneﬁt, early complications from
levodopa treatment, and slow progression. Parkin-associated
tremor-dominant parkinsonism includes a spectrum of late-
onset disorders without manifestations of foot dystonia,
hyperreﬂexia, diurnal ﬂuctuations, sleep beneﬁt, or early
susceptibility to levodopa-induced dyskinesia [2]. Therefore,
patients with PARK2 mutations are often clinically indistin-
guishablefromthose withsporadic Parkinson’s disease (PD).
PD patients exhibit decreased myocardial uptake of
meta-iodobenzylguanidine (MIBG) during 123I-MIBG
myocardial scintigraphy—a ﬁnding indicative of cardiac
sympathetic denervation [3]. Olfactory impairment, an early
symptom of PD, occurs in more than 70% of patients with
PD [4]. Rapid eye movement (REM) sleep behavior disorder
(RBD) is characterized by a loss of normal skeletal muscle
atonia and complex motor activity, speciﬁcally during REM
sleep associated with dream mentation. Thirty-eight percent
of RBD patients aged ≥ 50 years were eventually diagnosed
with PD [5]; therefore, RBD may serve as an early indicator
of PD.
Here,weexaminednonmotorsymptomsinpatientswith
PARK2 mutations.
2. Methods
Mutation of the parkin gene was conﬁrmed by gene analysis
[1]. Eight women and 7 men possessed mutations in the
PARK2 gene: cases 1, 2, 3, 8, and 13 carried homozygous-
deletions, andtheremainingcarried heterozygousmutations
or deletions (Table 1). Clinical ﬁndings and medications are
shown in Table 1.
T h eM I B Gs t u d yi n v o l v e d6w o m e na n d7m e n( m e a n
(SD) age, 58.5 (11.4) years) with PARK2 mutations: 5
subjects had homozygous deletions, and 8 had heterozy-
gous mutations or deletions. Patients had parkinsonism
for a mean (SD) period of 22.0 (11.59) years (range, 10–
44 years). When MIBG scintigraphy was performed, the
patients were not medicated with monoamine oxidase B
(MAOB) inhibitors, selective serotonin reuptake inhibitors,
or antidepressant drugs. Data was collected by E CAM
at 30 minutes and 3 hours after injection of 123I-MIBG2 Parkinson’s Disease
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.Parkinson’s Disease 3
(MyoMIBG-I 123 injection, 111 MBq; FUJIFILM RI Pharma
Co. Ltd.). The cut-oﬀ ratio of the heart to mediastinum
(H/M) uptake ratio of 123I-MIBG in our hospital was set at
1.45.
The olfactory function and polysomnography (PSG)
study involved 3 women and 3 men (mean (SD) age, 47.8
(13.2) years) with PARK2 mutations (Table 1).
The mean olfactory function scores of the PD patients
and 10 age-matched Japanese controls, who were evaluated
for comparison with patients with PARK2 mutations, were
determined by the Sniﬃn’ Sticks test. Mean age of the
controls without neurological disease or dementia was 46.0
(15.3) years (range, 39–79 years). The PD patients (mean
age, 69.6 (6.6) years; range, 60–89 years; not age matched to
patients with PARK2 mutations) fulﬁlled the UK Brain Bank
criteria for possible or probable clinical PD, with Hoehn-
Yahr stages II and III without dementia.
Olfactory testing was examined by following 3 com-
ponents. Olfactory threshold and odor discrimination and
identiﬁcation were investigated in 3 separate substrates
using standardized Sniﬃn’ Sticks [6]. Sniﬃn’ Sticks are
commercially available felt-tip pens.
Odor Thresholds. The olfactory threshold subset consisted
of 16 Sniﬃn’ Stick triplets with diﬀerent concentrations of
n-butanol. Three sticks were presented to the subject in
randomized order. Two contained only the solvent and the
third the odorant at a particular dilution. The subjects were
tasked to identify the stick with the odorant.
Odor Discrimination. In the odor discrimination subset, 16
Sniﬃn’ Stick triplets were presented in randomized order.
Two pens contained the same odorant and the third a
diﬀerent odorant. The task was to identify the stick that had
the diﬀerent smell.
Odor Identiﬁcation. The third subtest consisted of 16 single
sticks and assessed the ability to identify an odor. Using a
multiple-choice task, identiﬁcation of individual odorants
was performed from a list of 4 descriptors.
RBD was conﬁrmed by studying the patients’ clinical
history and video-PSG ﬁndings (International Classiﬁcation
of Sleep Disorders, 2nd edition) [7].
Informed consent was obtained from patients with
PARK2 mutations, and patients with PD, and normal
volunteers.
The data was statistically analyzed using SPSS ver.11 for
Windows.
3. Results
The mean H/M uptake ratio of 123I-MIBG scintigraphy in
PARK2 patients was 1.79 (0.31) in the early phase and 1.75
(0.51) in the delayed phase (Table 2). However, a 58-year-
old woman, with a 10-year disease duration and orthostatic
hypotension and constipation without myocardial damage,
exhibited accelerated MIBG elimination (H/M ratio: early,
1.23; delayed, 1.15). Three patients (cases 2, 7, and 12) had
exhibited slightly decreased uptake in the delayed phase.
The Sniﬃn’ Sticks test revealed a slight olfactory dys-
function with the following mean scores in examined PARK2
patients (Table 3): threshold score, 6.1 (1.6) (P<. 05 when
compared with controls); odor discrimination score, 10.0
(2.4); odor identiﬁcation score, 10.1 (4.8) (no signiﬁcant dif-
ferences when compared to controls). Odor discrimination
and identiﬁcation functions were not impaired in any of the
patients with PARK2 mutations, except in patient 1. In the
Japanese examined normative controls, the mean olfactory
function scores were as follows: threshold score, 8.0 (1.3);
discrimination score, 11.9 (2.4); identiﬁcation score, 10.9
(2.0); in PD patients, these mean scores were 2.2 (6.6), 6.1
(2.5), and 5.1 (1.8), respectively.
PSG did not reveal tonic responses in the mentalis and
tibialis muscles during REM (Table 3). Twitching of the
tibialis muscle was observed in 2 patients. None of the
patients with PARK2 mutations met the ICSD-II criteria for
RBD.
4. Discussion
Decreased 123I-MIBG uptake was observed clearly in 1
patient with PARK2 mutations who had autonomic dys-
function. Early phase myocardial uptake of MIBG in all of
the other patients showed no decrease, and patients had no
autonomic dysfunction. Similar to our study, in a previous
study [8], 1 of 4 patients with PARK2 mutations with a 12-
year disease duration and unclear autonomic dysfunction
exhibited decreased uptake of 123I-MIBG. Additionally, 3
patients in our study who showed decreased 123I-MIBG
uptake were slightly older than the other patients, although
a signiﬁcance in mean age (63.0 (9.1) versus 55.9 (10.8);
P>. 05) did not exist. Estorch et al. and Tsuchimochi
et al. reported that the uptake of 123I-MIBG decreased
with age, suggesting that aging could aﬀect patients with
PARK2 mutations [9, 10]. Decreased myocardial uptake
of MIBG is considered to indicate the presence of alpha-
synuclein aggregates in the axons in PD [11]. In MIBG-
myocardial scintigraphy, the H/M ratio of patients with
PARK2 mutations was reported to be within the range of the
normal controls [12]. Moreover, postmortem examination
of patients with PARK2 mutations revealed that tyrosine
hydroxylase immunoreactive nerve ﬁbers in the epicardium
were well preserved [13]. These ﬁndings might reﬂect
normal functioning myocardial sympathetic nerve terminals
inpatientswithPARK2mutations.MIBGscintigraphymight
be a marker for alpha-synuclein in patients with PARK2
mutations; however, there are no pathological reports on the
presence of Lewy bodies in patients with PARK2 mutations
exhibiting decreased MIBG uptake.
Olfactory impairment is a nonmotor symptom of PD.
We found that the olfactory threshold was slightly higher in
patients with PARK2 mutations than in controls. The oldest
woman in our study, who did not have dementia, exhibited
the highest degree of olfactory impairment. Although in self-
completed questionnaire study, 3 of 16 patients with PARK2
mutation had loss of taste/smell [14]. However, in previous4 Parkinson’s Disease
Table 2: The ﬁndings of 123IMIBG myocardial scintigraphy in PARK2 patients.
Case 1 2 3 5 7 8 9 10 11 12 13 14 Average ± SD
Examined age 65 55 46 41 76 70 63 61 61 60 57 44 58.3 ±10.5
Early H/M 2.27 1.64 1.91 1.75 1.52 2.05 1.75 1.66 1.23 1.75 1.62 2.35 1.79 ±0.31
Delay H/M 2.14 1.33 1.67 1.93 1.34 2.93 1.65 1.54 1.15 1.40 1.60 2.35 1.75 ±0.51
H/M: the heart to mediastinum uptake ratio of 123IMIBG.
Table 3: Olfactory function by Sniﬃn’ sticks and PSG study in patients with PARK2 mutation, controls, and Parkinson’s disease.
C a s e 123456 PARK2 total
(n = 6)
Control
(n = 10)
Parkinson’s disease
(n = 15)
A g e 7 15 54 64 13 83 6 4 7 .8 ±13.24 6 .0 ±15.36 9 .6 ±6.6
Sniﬃn’ sticks Test
Threshold test 4.5 6.3 6.3 5.8 5.0 9.0 6.1 ±1.68 .0 ±1.3∗ 2.2 ±2.3∗∗
Discrimination test 8.0 9.0 12.0 14.0 9.0 8.0 10.0 ±2.41 1 .9 ±2.46 .1 ±2.5
Identiﬁcation test 1.0 13.0 10.0 14.0 13.0 10.0 10.1 ±4.81 0 .9 ±2.05 .1 ±1.8
PSG ﬁndings
Apnea index (times/H) 10.1 22.5 1.2 0.4 1.0 2.1
Hypopnea index (times/H) 2.2 14.0 4.7 0.3 1.9 9.4
Apnea Hypopnea index
(times/H) 12.3 36.5 5.9 0.8 3.0 11.4
Arousal index (times/H) 16.0 39.8 37.7 13.4 14.3 11.1
Respiratory arousal index
(times/H) 5.5 27.3 4.6 0.2 1.6 3.3
PLM index(times/H) 7.8 0.0 7.7 0.0 29.5 0.0
PLM arousal index(times/H) 0.0 0.0 5.3 0.0 2.8 0.0
REM sleep twitching on TA
muscle
− + − + −−
H/M: theheart to mediastinum uptake ratio, NE: not examined.
PLM: periodic limb movements, TA: tibialis anterior.
∗t-test: compared with PARK2 patients P<. 05.
∗∗t-test: compared with PARK2 patients and control P<. 01.
studies, individuals with PARK2 mutations were found to
have normal olfactory function [15, 16]. The discrepancy
between our results and previous ones may be because
previous studies used the Pennsylvania Smell Identiﬁcation
Test, which does not include the threshold test. In Kahn’s
study [15], the odor identiﬁcation score did not signiﬁcantly
diﬀer between patients with PARK2 mutations and controls,
although this did not necessarily imply that the threshold
score was normal in the patients.
PSG did not reveal RBD in any of our patients. However,
in a study by Kumru et al., 6 of 10 patients had RBD
[17]. We cannot explain this discrepancy, but we hypothesize
that it may be due to the diﬀerences in patient mean age
between the 2 studies. Some of our patients with PARK2
mutationshavetwitchinginthetibialismuscle;therefore,the
possibility that they will eventually develop RBD cannot be
ruledout.NeuropathologicalstudiesonpatientswithPARK2
mutations have revealed neuronal loss and gliosis in the pars
compacta of the substantia nigra and in the locus coeruleus
[18]. However, these studies have not described the state of
the subcoeruleus nucleus, which is considered the primary
site aﬀected in RBD.
The results obtained in this study suggest that some
patients with PARK2 mutations have increased thresholds of
olfactory function and myocardial sympathetic dysfunction
as nonmotor symptoms. We might show that the nonmotor
symptoms of PARK2 were impaired heterogeneously.
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